abstract |
The present invention provides methods for treating diseases associated with selective subtype modulation of alpha 2 adrenergic receptors. In particular, the present invention provides well-defined N- [1- (2 and / or 3-substituted phenyl) -alkyl]-(4,5-dihydro-1H-imidazol-2-yl) -amines and pharmaceutical compositions thereof. The present invention provides methods for treating diseases associated with selective subtype alpha 2 adrenergic receptor modulation. |